Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Spiramycin activity against acute pneumonia has been studied in 21 outpatients (15 adults and 6 children). The drug was administered orally twice daily in a dose 3,000,000 units. The course lasted from 7 to 14 days. All the cases were confirmed roentgenologically. The disease ran a moderate-severity course. The response rate reached 95.2%. Another course of antibiotic therapy was not needed. Side effects were not registered. Bacteriological efficacy of spiramycin made up 71.3%. 14 out of 16 isolated strains of causative agents (S.pneumoniae, S.pyogenes, S.aureus, H.influenzae in 5, 1, 7 and 3 patients, respectively) proved sensitive to spiramycin. 2 patients developed mycoplasma infection diagnosed serologically. The findings confirm high therapeutic efficacy of spiramycin, its good tolerance. Spiramycin may be considered the drug of the priority choice in outpatient treatment of acute pneumonia.
 ...
PMID:[Spiramycin (rovamycin), a macrolide antibiotic for oral treatment of outpatient pneumonia]. 760 19

An open non-comparative study of rovamycin (spiramycin produced by Rhone-Poulenc Rorer) for intravenous administration was performed to evaluate its clinical and bacteriological efficacy, safety and tolerance. Thirty patients (adults aged 16-65 years) with community-acquired pneumonia were involved into the study. Two patients were dropped out because of adverse events. Dosage regimen was 1,500,000 I.U. three times a day (intravenous infusion). The treatment was continued after partial recovery (3,000,000 I.U. per os). Spiramycin showed a high clinical efficacy. Approximately half of the patients (41.4-55.6%) had positive clinical trends by third day of spiramycin treatment. The overall clinical efficacy by the completion of the drug administration reached 90.0%. Bacteriological activity was observed in 93.4% of the patients treated. Adverse events were observed in 6 (20.0%) patients, including 2 dropouts. Serious side effects were not registered. As rovamycin showed high clinical efficacy and good safety the drug may be recommended for the treatment of adult pneumonia.
 ...
PMID:[Rovamycin (spiramycin)--a macrolide antibiotic for intravenous administration: a trial in the treatment of pneumonia]. 777 Aug 11

This open multicentre study compared the efficacy and tolerability of clarithromycin and spiramycin in the treatment of lower respiratory tract infections in Brazil and Colombia. A total of 125 patients with a clinical and radiological diagnosis of pneumonia, acute bronchitis or exacerbation of chronic bronchitis were randomised to receive oral doses of either clarithromycin (500 mg) or spiramycin (3 MIU) every 12 hours for courses of 5-10 days. Patients were assessed before the start of treatment, and at days 3-4 and days 9-17. Twenty-six (26) patients (16 in the spiramycin group and 10 in the clarithromycin group) reported adverse events, seven of whom withdrew from the trial. Statistical analysis detected no significant differences between efficacy (p = 0.768) or tolerability (p = 0.236) for the two treatment groups. Spiramycin therefore has similar efficacy to clarithromycin in the treatment of community-acquired lower respiratory tract infections.
 ...
PMID:Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections. 1062 70